Enhanced Approaches to the Identification, Evaluation, and Control of Impurities
- 234 Downloads
A series of case histories from IQ consortium member companies will be presented to exemplify how the application of the ICH Q11 vision for enhanced or quality by design (QbD) development for the active pharmaceutical ingredient (API) can lead to differentiated outcomes for elements such as the API supply chain and control strategy, and how changes to such outcomes are managed over the lifecycle. A series of articles will address “flexibility” and look to provide recommendations for the further development of the ICH Q11 vision. The focus of this work will address flexibility associated with the “Enhanced Approaches to the Identification, Evaluation and Control of Impurities.”
KeywordsICH Q11 Chemistry Control strategy Quality by design QbD Process Methods Models CMC Regulatory flexibility PAT ATP
The authors acknowledge the following for their input and support: Dave White, Kevin Seibert, Tim Watson, Steve Tymonko, Lindsay Hobson, Sushil Srivastava, Adam Looker, Asher Lower, John R Donaubauer, Nathan Ide, and John Lepore.
- 1.International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals For Human Use; ICH Q11 Development and Manufacture of Drug Substances (chemical entities and biotechnological/biological entities), Geneva, Switzerland, 2012.Google Scholar
- 2.Popkin ME, Borman PJ, Omer BA, Seibert KD, Srivastava S, Lepore JV, Hobson L, Donaubauer J, Curran T, Ide N, Tymonko S, Looker A. The delivery of flexibility from the application of QbD to API development. J Pharm Innov. 2018;13(4):367. Google Scholar
- 3.International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use; ICH QM7 Assessment and control of DNA reactive (mutagenic) Impurities in Pharmaceuticals, Geneva, Switzerland, 2015.Google Scholar
- 4.Teasdale A, Elder D, Fenner S. Genotoxic impurities, strategies for identification and control (chapter 9 strategies for the evaluation of genotoxic impurity risk). New Jersey: Wiley; 2010. p. 221–48.Google Scholar
- 7.Hemingway R. Mirabilis, 46th ICGM, Baltimore. 16th March 2017, https://www.lhasalimited.org/publications/mirabilis-semi-automated-prediction-of-purge-factors/4310.
- 9.Schweitzer M, Pohl M, Hanna-Brown M, Nethercote P, Borman P, Hansen G, et al. Implications and opportunities of applying QbD principles to analytical measurements. Pharm Technol. 2010;34(2):52–9.Google Scholar
- 10.Borman P, Roberts J, Jones C, Hanna-Brown M, Szucs R, Bale S. The development phase of an LC method using QbD principles. Sep Sci. 2010;2:2–8.Google Scholar
- 11.Martin G. P., Barnett K. L., Burgess C., Curry P. D., Ermer J., Gratzl G. S., Hammond J. P., Herrmann J., Kovacs E., LeBlond D. J., LoBrutto R., McCasland-Keller A. K., McGregor P. L., Nethercote P., Templeton A. C., Thomas D. P., Weitzel M. L. J., Lifecycle management of analytical procedures: method development, procedure performance qualification, and procedure performance verification, Pharmacopeial Forum, 2013, 39(5).Google Scholar
- 12.Barnett K.L., McGregor P.L., Martin G.P., Le Blond D.J., Weitzel M.L.J., Ermer J., Walfish S., Nethercote P., Gratzl G.S., Kovacs E., Pappa H., Analytical target profile: structure and application throughout the analytical, Pharmacopeial Forum, 2016, 42(5).Google Scholar
- 13.International Conference on Harmonisation of technical requiremens for registration of pharmaceuticals for human use; ICH Q8R2 pharmaceutical development, Geneva, Switzerland, 2009.Google Scholar
- 14.EMA-FDA pilot program for parallel assessment of Quality-by-Design applications: lessons learnt and Q&A resulting from the first parallel assessment, 20 August 2013.Google Scholar
- 15.Borman P, Chatfield M, Jackson P, Laures A, Okafo G. Reduced method robustness testing of analytical methods driven by a risk-based approach. Pharm Technol Eur. 2010;22(4):38–47.Google Scholar
- 17.International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use; ICH Final Concept Paper Q12: Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management, Geneva, Switzerland, 9 Sep 2014 http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q12/Q12_Draft_Guideline_Step2_2017_1116.pdf.
- 18.Borman P, Chatfield M, Nethercote P, Thompson D, Truman K. The application of quality by design to analytical methods. Pharm Technol. 2007;31(10):142–52.Google Scholar
- 20.Abdel-Kader H, Argentine M, Benz N, Burdick R, Chatfield M, Diana F, et al. Analytical method comparability in registration and post-approval stages: a risk-based approach. Pharm Technol. 2014;38(10):60–70.Google Scholar